Pharmaceuticals - Aurobindo Research and Development
Aurobindo Pharma’s migration from pure generics to increasing presence in sterile and controlled substances, coupled with presence in branded generics, will be margin accretive for the company. The revenue estimates for FY11 have been upgraded by 5 per cent to Rs.42.5 billion and for FY12 by 11 per cent to Rs.52.1 billion.
They have also upgraded their EPS estimates for FY11 by 18 per cent to Rs.97.8 (better operating performance and accounting for forex gains) and by all percent to U15.2 for FY12. The company’s current price performance has receded FCCB concerns. The target price has been upgraded by 29 per cent to Rs.1525 and rate stock
No comments:
Post a Comment